Israel’s NeuraLight (see here) and NeuroSense Therapeutics (see here) are partnering to improve the diagnosis and monitoring of Amyotrophic lateral sclerosis (ALS). They will study patients using NeuroSense’s biological markers, together with Neuralight’s digital oculometric biomarkers.
Startups partner to detect ALS
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.